Pharma Likelihood Of Approval
We are the trusted, gold standard intelligence provider to the world’s largest industries
GlobalData powers faster, more informed decisions with:
- Granular industry intelligence: We develop deep, vertical-specific intelligence tailored to your industry, providing 360° insight.​
- Exhaustive coverage: We synthesize our vast data universe into formats that support your decision-making needs, covering the sectors, themes, companies and geographies that matter to you. ​
- Proprietary datasets: We provide you with access to untapped pools of intelligence generated from our proprietary datasets and primary research capabilities. ​
- Robust methodologies: The quality and timeliness of our data is a key differentiator. We leverage robust research methodologies to turn millions of data points into trusted intelligence.
Thousands of companies, government organizations, and decision makers rely on GlobalData
We have a track record of serving truly diverse clients, including:
- Corporates: From helping the C-suite refine strategy to powering innovation in marketing and R&D, our corporate use cases are endless. ​
- Investment firms: We help financial analysts develop robust long-term strategies and get alpha signals before the rest. ​
- Professional services: We give consultants, legal, and accounting firms the critical insights to make faster, more informed decisions. ​
- Other sectors: From media to academia, we work with sectors as diverse as our data. ​
The trusted, actionable and future-proof insight you need to stay ahead
We have decades of experience in being the gold standard intelligence provider based on: ​
- Unique data: Proprietary datasets built from terabytes of data. Our unmatched intelligence gives you true strategic advantage.
- Expert analysis: Leverage collective expertise. Count on our extensive team of researchers, analysts, subject matter experts, and journalists, plus thousands of external thought-leaders.​
- Real intelligence over AI: Experience a level of analysis that leaves AI in the dust. Unlock the proprietary datasets unseen by AI and gain a decisive edge. ​
- Time-saving research solutions: Save hundreds of hours on research. Our comprehensive reports let you focus on delivering actionable insights - not searching for them. ​
- Unparalleled global coverage: Tap into insights from anywhere. Our extensive global coverage offers an unrivalled view of the market landscape.​
- One platform: Access all our unique data, expert analysis, and innovative solutions on one platform. ​
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model - Cobimetinib Fumarate in Low-Grade Glioma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Cobimetinib Fumarate in Low-Grade Glioma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Cobimetinib Fumarate in Low-Grade GliomaDrug Details:Cobimetinib (GDC-0973 / RG7421 / Cotellic) acts...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model - Cobimetinib Fumarate in Pediatric Diffuse Intrinsic Pontine Glioma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Cobimetinib Fumarate in Pediatric Diffuse Intrinsic Pontine Glioma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Cobimetinib Fumarate in Pediatric Diffuse Intrinsic Pontine GliomaDrug Details:Cobimetinib...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model - Cobimetinib Fumarate in Atypical Teratoid Rhabdoid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Cobimetinib Fumarate in Atypical Teratoid Rhabdoid Tumor report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Cobimetinib Fumarate in Atypical Teratoid Rhabdoid TumorDrug Details:Cobimetinib (GDC-0973 /...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model - Secukinumab in Lupus Nephritis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Secukinumab in Lupus Nephritis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Secukinumab in Lupus Nephritis Drug Details: Secukinumab (Cosentyx, Zafrez, Fraizeron) is an...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model - XL-888 in Colorectal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - XL-888 in Colorectal Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. XL-888 in Colorectal Cancer Drug Details: XL-888 is under development for...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model - PD-0360324 in Head And Neck Cancer Squamous Cell Carcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - PD-0360324 in Head And Neck Cancer Squamous Cell Carcinoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.PD-0360324 in Head And Neck Cancer Squamous Cell...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model - Surufatinib in Ewing Sarcoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Surufatinib in Ewing Sarcoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Surufatinib in Ewing Sarcoma Drug Details: Surufatinib (Sulanda) is a potential...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model - Surufatinib in Rhabdomyosarcoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Surufatinib in Rhabdomyosarcoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Surufatinib in Rhabdomyosarcoma Drug Details: Surufatinib (Sulanda) is a potential antineoplastic and...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model - Canakinumab in Pancreatic Ductal Adenocarcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Canakinumab in Pancreatic Ductal Adenocarcinoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Canakinumab in Pancreatic Ductal Adenocarcinoma Drug Details: Canakinumab (Ilaris / Lasprona...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model - Deupirfenidone in Lymphedema
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Deupirfenidone in Lymphedema report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Deupirfenidone in LymphedemaDrug Details: Deupirfenidone (SD-560, LYT-100) is under development for the treatment of...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.